Ranbaxy’s Controversial India Plant Gets Australian, U.K. Regulatory Approvals

Ranbaxy Laboratories (Gurgaon, India) says that the Medicines and Healthcare products Regulatory Agency (MHRA; London) of the U.K., and the Therapeutic Goods Administration (TGA; Canberra), Australia’s drug regulatory body, have issued good manufacturing practice (GMP) certificates for Ranbaxy’s Paonta Sahib, India manufacturing facility, following a joint audit conducted last October. Ranbaxy says that the MHRA approval will cover product filings for the U.K. and also apply to product filings for the entire European Union. The U.S. FDA said last...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers